RELEVANT EVENTS

December 31, 2014
Grifols receives FDA approval for its new purification plant to produce Gamunex in Los Angeles

November 26, 2014
Payment of interim dividend on account of 2014 profit

November 17, 2014
Grifols receives FDA approval for its new fractionation plant in Clayton

October 21, 2014
The board of directors approves the payment of an interim dividend on account of 2014 earnings

September 19, 2014
Grifols subscribes to a capital increase of the company Kiro Robotics, S.L.

May 30, 2014
Information on the resolutions approved at the Annual General Meeting of Shareholders on May 30, 2014

May 29, 2014
Senior Unsecured notes admitted to listing in the Irish Stock Exchange

April 25, 2014
Notice of Annual General Shareholders' Meeting 2014

April 4, 2014
Grifols opens new plasma fractionation plant in Spain (Press release)

March 31, 2014
The Japanese Red Cross signs a seven-year agreement to use Grifols' Procleix Nucleic acid blood screening systems

March 17, 2014
Grifols has concluded the refinancing process of its debt

March 6, 2014
Grifols issues $1billion senior unsecured notes

February 24, 2014
Grifols starts the refinancing process

February 24, 2014
Appointment of new president of the Audit Committee

January 10, 2014
Grifols closes the acquisition of Novartis AG diagnostic business unit

January 3, 2014
Grifols signs a US$1.5billion bridge loan that will be used to acquire the diagnostic business unit of Novartis AG

December 17, 2013
Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 17, 2013

November 20, 2013
Grifols communicates the acquisition of 21.30% of the biotechnological company TiGenix N.V.

November 15, 2013
Notice of Extraordinary General Shareholders' Meeting December 2013

November 11, 2013
Grifols to acquire Novartis diagnostics business unit for US$1,675 million

September 18, 2013
Grifols, S.A. informs the start of a clinical trial in phase I of the ABvac40 vaccine for patients with Alzheimer's disease

August 28, 2013
Grifols informs of the closing of the subscription of the shares of Aradigm Corp

July 15, 2013
Grifols informs that Moody's Investors Services has upgraded the company credit ratings

May 24, 2013
Information on the resolutions approved at the Annual General Shareholders Meeting on May 24, 2013

May 21, 2013
Grifols signs an exclusive worldwide license agreement with Aradigm to develop and commercialize Pulmaquin™

April 22, 2013
Notice of Annual General Shareholders' Meeting 2013

April 19, 2013
New non-voting class B shares admitted to listing

April 16, 2013
Registration with the Commercial Registry of the share capital increase and the issuance of new Class B non-voting shares

March 12, 2013
Grifols purchases ADRs from Cerberus'

March 4, 2013
Grifols announces the acquisition of 60% of the share capital of Progenika Biopharma S.A.

January 11, 2013
New non-voting class B shares admitted to listing

January 4, 2013
Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares

December 10, 2012
Announcement of Grifols S.A Share Capital Increase

December 4, 2012
Information on the proposals adopted by the Extraordinary General Shareholders Meeting on December 4, 2012

November 30, 2012
The US Department of Justice (DOJ) notified of the official declination to all inquiries that were underway since July 2009 in Talecris

October 29, 2012
Notice of Extraordinary General Shareholders' Meeting December 2012

September 19, 2012
CNMV Communications

August 1, 2012
Standar & Poor´s: Rating upgrade

July 23, 2012
ADS's Exchange Ratio Modification

July 9, 2012
Grifols informs that Moody's Investors Services has upgraded its ratings

May 24, 2012
Information on the resolutions approved at the Annual General Shareholders Meeting on May 24, 2012

April 20, 2012
Notice of General Shareholders' Meeting 2012

March 15, 2012
Grifols, S.A. announces that it has acquired 51% of the share capital of Araclon Biotech, S.L.

February 14, 2012
Grifols informs that has successfully closed the negotiations to amend and improve the terms and conditions of the Credit Agreement

January 18, 2012
CNMV Communication

December 29, 2011
New non-voting class B shares admitted to listing in Spain Download (70,95 Kb)

December 22, 2011
Registration with the Commercial Registry of the share capital increase and the issuance of the new Class B non-voting shares

December 5, 2011
Announcement of Grifols S.A Share Capital Increase

December 2, 2011
Information on the resolutions approved at the Extraordinary General Shareholders Meeting on December 2, 2011

November 8, 2011
3Q results reporting date postponed

October 28, 2011
Notice of Extraordinary General Shareholders' Meeting December 2011

August 2, 2011
Grifols announces the closing of the transaction to acquire 100% of the capital of the Australian-Swiss group, Lateral-Medion

June 3, 2011
Execution of the agreement with Kedrion

June 2, 2011
Closing of the acquisition of Talecris Biotherapeutics

June 1, 2011
Grifols and Talecris announce that the FTC accepted for public comment the Consent Agreement

June 1, 2011
Changes in the board of directors

June 1, 2011
Registration of the "Nota sobre Acciones" (Securities Note) of the Class B non voting shares with the "CNMV" (National Securities Market Commission)

May 24, 2011
Information on the resolutions approved at the Ordinary general shareholders meeting

May 2, 2011
Grifols and Talecris Biotherapeutics announce the signing of a Consent Agreement with FTC Staff

April 19, 2011
Notice of Annual General Shareholders Meeting 2011

March 4, 2011
Grifols and Talecris disclose the extension of the outside date under their merger agreement and the financing commitments

February 11, 2011
New timing agreement with the FTC to provide advance notice of the consummation of the acquisition of Talecris

February 4, 2011
Agreement with the FTC to extend the timing of the resolution for the acquisition of Talecris

January 25, 2011
Information of the resolutions passed at the Extraordinary General Shareholders Meeting held January 25th 2011

January 17, 2011
Filing with the Securities Exchange Commission of the F-4 relating to the proposed acquisition of Talecris

January 13, 2011
Grifols closes USD 1.1 billion bond issue (This release will not be distributed in the United States of America, Canada, Australia or Japan)

December 20, 2010
Notice of Extraordinary General Meeting

December 15, 2010
Grifols obtains EMA license to market its IVIG, Flebogamma® DIF, at 10% concentration

November 24, 2010
Grifols signs term loan agreements related to Talecris acquisition for USD 3.4 billion

November 11, 2010
Changes in the merger consideration of the Agreement and Plan of Merger as a consequence of the settlement of a class action

November 4, 2010
Resolution by the " Commisión Nacional de la Competencia"

November 2, 2010
Clarification on press releases published in certain media

September 30, 2010
Shareholders' commitment to the proposed acquisition of Talecris

September 15, 2010
Grifols expects to close for an amount of USD1.5B the first tranche of the syndicated Financing to acquire Talecris

September 2, 2010
Grifols obtains FDA license in the US market for its IVIG Flebogamma® DIF 10% concentration

August 10, 2010
Preliminary version of the F4 filed with the SEC in connection with the proposed acquisition of Talecris

July 20, 2010
Grifols obtains its first crédit rating from Standard & Poor's and Moody's

June 23, 2010
Final dividend 2009

June 21, 2010
Information on the resolutions passed at the Annual General Shareholders Meeting on June 21st

June 10, 2010
Voting agreement - amendment

June 10, 2010
Agreement and Plan of Merger among Grifols and Talecris Biotherapeutics Holdings Corp

June 7, 2010
Acquisition Announcement of Talecris Biotherapeutics Holdings Corp

June 7, 2010
Voting agreement

June 7, 2010
Analyst and investors' presentation regarding acquisition of Talecris Biotherapeutics Holdings Corp

June 7, 2010
Conference call details

May 18, 2010
Notice of Annual General Meeting

January 12, 2010
Resignation of Christian Purlow from the Board of Directors

December 16, 2009
Grifols and financial institutions unanimously agree the novation of the syndicated facility

December 14, 2009
Interim Dividend 2009 - Clarification

December 14, 2009
Interim Dividend 2009

November 3, 2009
Change of registered address

October 7, 2009
Grifols completes its USD600 million corporate bond issue in the US

September 29, 2009
Grifols announces corporate debt issuance in USA

May 28, 2009
The shares of Grifols will be traded in the United States through ADRs

May 20, 2009
Announcement on Grifols dividend payment

May 15, 2009
Information on the resolutions passed by the General Shareholders' Meeting held on May 15th, 2009

April 7, 2009
Annual General Meeting Announcement

March 31, 2009
Grifols signs two supply agreements in brazil

March 3, 2009
Grifols acquires control over a Swiss and Australian group through a €25 million investment

December 10, 2008
D. Anna Veiga joins the Board of Directors of Grifols as independent director (Spanish Version)

October 14, 2008
Flebogamma® DIF receives marketing license in Australia (Spanish Version)

June 13, 2008
The Company submits agreements approved in the Annual General Meeting on June 13, 2008 (Spanish Version)

June 13, 2008
The Company announces a dividend payment for June 23, 2008 (Spanish Version)

May 26, 2008
Grifols obtains a syndicated loan totaling 350 million euros (Spanish Version)

May 22, 2008
Annual General Meeting Announcement Addendum (Spanish Version)

May 7, 2008
Annual General Meeting Announcement (Spanish Version)

April 29, 2008
The Company notifies the resignation of Mr. Thomas E. Doster from his positions as member of the Board of Directors and the Appointments and Remunerations Committee (Spanish Version)

March 12, 2008
Grifols signs agreement with Stough Development Corporation to open 10 new plasma collection Centers in the United States (Spanish Version)

February 23, 2008
Grifols closed without agreement the due diligence process started with the Italian company Diesse (Spanish Version)

December 21, 2007
Appointment of Edgar D. Jannotta as member of the Appointments and Remuneration Committee (Spanish Version)

October 29, 2007
Grifols to announce Capital Investment Plan for 400 million euro over the next five years

August 27, 2007
EMEA authorization to distribute Flebogamma DIF® in Europe (Spanish Version)

August 10, 2007
Announcement of transfer of shares (Spanish Version)

June 26, 2007
Announcement on Grifols dividend payment (Spanish Version)

June 21, 2007
Information on the resolutions passed by the General Shareholders Meeting held on June 20th, 2007 (Spanish Version)

May 14, 2007
Annual General Meeting Announcement (Spanish Version)

May 4, 2007
Grifols enters into an agreement for the management of four new plasma centers in the USA (Spanish Version)

April 18, 2007
Grifols has entered into an agreement for the acquisition of Diesse. The closing of the transaction is subject to the outcome of the due diligence review, which the company expects will last until next June. (Spanish Version)

April 10, 2007
Morgan Stanley & Co. International Ltd announces the completion of the placement (Spanish Version)

April 10, 2007
Morgan Stanley & Co. International Ltd announces a private placement of 1.41% of Grifols S.A. share capital (accelerated bookbuilding) (Spanish Version)

February 2, 2007
Extension of the Communication number 22.629 on the FDA approval for the indication of von Willebrand disease. (Spanish Version)

February 1, 2007
The FDA approves the indication of von Willebrand disease for Alphanate (Spanish Version)

December 27, 2006
Grifols licensed by the FDA to market a new generation of IGIV in the United States (Spanish version)

December 20, 2006
Appointment of new Director through co-option procedure (Spanish version)

November 21, 2006
Amendment to the syndicated loan (Spanish version)

July 19, 2006
Changes in the Board of Directors and other governing bodies of the Company (Spanish version)

June 19, 2006
Public Offering to subscribed Grifols S.A. shares – additional information ( Spanish version)

May 22, 2006
Information regarding the execution of the green shoe option over 7,000,000 shares of Grifols (Spanish version)

May 16, 2006
Additional information to the information brochure of the public subscription offer for shares in GRIFOLS, S.A. (Spanish version)

May 15, 2006
Additional information to the information brochure of the public subscription offer for shares in GRIFOLS, S.A. (Spanish version)